Loading...
XJPX
7096
Market cap48mUSD
Jul 10, Last price  
768.00JPY
1D
0.92%
1Q
2.13%
IPO
-60.82%
Name

StemCell Institute

Chart & Performance

D1W1MN
XJPX:7096 chart
P/E
50.47
P/S
2.80
EPS
15.22
Div Yield, %
3.29%
Shrs. gr., 5y
0.74%
Rev. gr., 5y
14.81%
Revenues
2.81b
+4.93%
1,676,000,0001,409,515,0001,781,943,0002,091,293,0002,481,193,0002,679,175,0002,811,344,000
Net income
156m
-59.59%
277,000,00062,371,000133,726,000198,032,000310,981,000385,796,000155,917,000
CFO
74m
-84.28%
667,859,000238,996,000469,290,00099,672,000334,625,000467,685,00073,509,000
Dividend
Sep 27, 202425 JPY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

StemCell Institute Inc. provides specialized stem cell banking services throughout Japan. In addition to its core preservation activities, the company is deeply involved in the research and development of medical therapies that utilize stem cells, and it also offers banking solutions for blood vessel cells. Founded in 1999, StemCell Institute Inc. is headquartered in Tokyo, Japan, and operates as a subsidiary of Trim Medical Holdings Inc.
IPO date
Jun 25, 2021
Employees
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2026‑032025‑032024‑032023‑032022‑032021‑032020‑032019‑032018‑03
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT